

Uterine Cancer Therapies and Diagnostic Market - Global Outlook and Forecast 2022-2028

<https://marketpublishers.com/r/U845D300A1F6EN.html>

Date: March 2022

Pages: 66

Price: US\$ 3,250.00 (Single User License)

ID: U845D300A1F6EN

Abstracts

Uterine cancer is a common form of cancer of the female reproductive system that initiates in the lining of the uterus.

This report contains market size and forecasts of Uterine Cancer Therapies and Diagnostic in Global, including the following market information:

Global Uterine Cancer Therapies and Diagnostic Market Revenue, 2017-2022, 2023-2028, (\$ millions)

Global top five companies in 2021 (%)

The global Uterine Cancer Therapies and Diagnostic market was valued at 21200 million in 2021 and is projected to reach US\$ 28410 million by 2028, at a CAGR of 4.3% during the forecast period.

The U.S. Market is Estimated at \$ Million in 2021, While China is Forecast to Reach \$ Million by 2028.

Uterine Sarcomas Segment to Reach \$ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Uterine Cancer Therapies and Diagnostic include Ariad Pharmaceuticals, Merck, AbbVie and BD, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Uterine Cancer Therapies

and Diagnostic companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Uterine Cancer Therapies and Diagnostic Market, by Type, 2017-2022, 2023-2028 (\$ millions)

Global Uterine Cancer Therapies and Diagnostic Market Segment Percentages, by Type, 2021 (%)

Uterine Sarcomas

Endometrial Carcinomas

Global Uterine Cancer Therapies and Diagnostic Market, by Application, 2017-2022, 2023-2028 (\$ millions)

Global Uterine Cancer Therapies and Diagnostic Market Segment Percentages, by Application, 2021 (%)

Hospitals

Ambulatory Surgical Centers

Specialty Clinics

Others

Global Uterine Cancer Therapies and Diagnostic Market, By Region and Country, 2017-2022, 2023-2028 (\$ Millions)

Global Uterine Cancer Therapies and Diagnostic Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Uterine Cancer Therapies and Diagnostic revenues in global market, 2017-2022 (estimated), (\$ millions)

Key companies Uterine Cancer Therapies and Diagnostic revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

Ariad Pharmaceuticals

Merck

AbbVie

BD

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

- 1.1 Uterine Cancer Therapies and Diagnostic Market Definition
- 1.2 Market Segments
 - 1.2.1 Market by Type
 - 1.2.2 Market by Application
- 1.3 Global Uterine Cancer Therapies and Diagnostic Market Overview
- 1.4 Features & Benefits of This Report
- 1.5 Methodology & Sources of Information
 - 1.5.1 Research Methodology
 - 1.5.2 Research Process
 - 1.5.3 Base Year
 - 1.5.4 Report Assumptions & Caveats

2 GLOBAL UTERINE CANCER THERAPIES AND DIAGNOSTIC OVERALL MARKET SIZE

- 2.1 Global Uterine Cancer Therapies and Diagnostic Market Size: 2021 VS 2028
- 2.2 Global Uterine Cancer Therapies and Diagnostic Market Size, Prospects & Forecasts: 2017-2028
- 2.3 Key Market Trends, Opportunity, Drivers and Restraints
 - 2.3.1 Market Opportunities & Trends
 - 2.3.2 Market Drivers
 - 2.3.3 Market Restraints

3 COMPANY LANDSCAPE

- 3.1 Top Uterine Cancer Therapies and Diagnostic Players in Global Market
- 3.2 Top Global Uterine Cancer Therapies and Diagnostic Companies Ranked by Revenue
- 3.3 Global Uterine Cancer Therapies and Diagnostic Revenue by Companies
- 3.4 Top 3 and Top 5 Uterine Cancer Therapies and Diagnostic Companies in Global Market, by Revenue in 2021
- 3.5 Global Companies Uterine Cancer Therapies and Diagnostic Product Type
- 3.6 Tier 1, Tier 2 and Tier 3 Uterine Cancer Therapies and Diagnostic Players in Global Market
 - 3.6.1 List of Global Tier 1 Uterine Cancer Therapies and Diagnostic Companies

3.6.2 List of Global Tier 2 and Tier 3 Uterine Cancer Therapies and Diagnostic Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview

4.1.1 by Type - Global Uterine Cancer Therapies and Diagnostic Market Size Markets, 2021 & 2028

4.1.2 Uterine Sarcomas

4.1.3 Endometrial Carcinomas

4.2 By Type - Global Uterine Cancer Therapies and Diagnostic Revenue & Forecasts

4.2.1 By Type - Global Uterine Cancer Therapies and Diagnostic Revenue, 2017-2022

4.2.2 By Type - Global Uterine Cancer Therapies and Diagnostic Revenue, 2023-2028

4.2.3 By Type - Global Uterine Cancer Therapies and Diagnostic Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview

5.1.1 By Application - Global Uterine Cancer Therapies and Diagnostic Market Size, 2021 & 2028

5.1.2 Hospitals

5.1.3 Ambulatory Surgical Centers

5.1.4 Specialty Clinics

5.1.5 Others

5.2 By Application - Global Uterine Cancer Therapies and Diagnostic Revenue & Forecasts

5.2.1 By Application - Global Uterine Cancer Therapies and Diagnostic Revenue, 2017-2022

5.2.2 By Application - Global Uterine Cancer Therapies and Diagnostic Revenue, 2023-2028

5.2.3 By Application - Global Uterine Cancer Therapies and Diagnostic Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Uterine Cancer Therapies and Diagnostic Market Size, 2021 & 2028

6.2 By Region - Global Uterine Cancer Therapies and Diagnostic Revenue & Forecasts

6.2.1 By Region - Global Uterine Cancer Therapies and Diagnostic Revenue, 2017-2022

6.2.2 By Region - Global Uterine Cancer Therapies and Diagnostic Revenue, 2023-2028

6.2.3 By Region - Global Uterine Cancer Therapies and Diagnostic Revenue Market Share, 2017-2028

6.3 North America

6.3.1 By Country - North America Uterine Cancer Therapies and Diagnostic Revenue, 2017-2028

6.3.2 US Uterine Cancer Therapies and Diagnostic Market Size, 2017-2028

6.3.3 Canada Uterine Cancer Therapies and Diagnostic Market Size, 2017-2028

6.3.4 Mexico Uterine Cancer Therapies and Diagnostic Market Size, 2017-2028

6.4 Europe

6.4.1 By Country - Europe Uterine Cancer Therapies and Diagnostic Revenue, 2017-2028

6.4.2 Germany Uterine Cancer Therapies and Diagnostic Market Size, 2017-2028

6.4.3 France Uterine Cancer Therapies and Diagnostic Market Size, 2017-2028

6.4.4 U.K. Uterine Cancer Therapies and Diagnostic Market Size, 2017-2028

6.4.5 Italy Uterine Cancer Therapies and Diagnostic Market Size, 2017-2028

6.4.6 Russia Uterine Cancer Therapies and Diagnostic Market Size, 2017-2028

6.4.7 Nordic Countries Uterine Cancer Therapies and Diagnostic Market Size, 2017-2028

6.4.8 Benelux Uterine Cancer Therapies and Diagnostic Market Size, 2017-2028

6.5 Asia

6.5.1 By Region - Asia Uterine Cancer Therapies and Diagnostic Revenue, 2017-2028

6.5.2 China Uterine Cancer Therapies and Diagnostic Market Size, 2017-2028

6.5.3 Japan Uterine Cancer Therapies and Diagnostic Market Size, 2017-2028

6.5.4 South Korea Uterine Cancer Therapies and Diagnostic Market Size, 2017-2028

6.5.5 Southeast Asia Uterine Cancer Therapies and Diagnostic Market Size, 2017-2028

6.5.6 India Uterine Cancer Therapies and Diagnostic Market Size, 2017-2028

6.6 South America

6.6.1 By Country - South America Uterine Cancer Therapies and Diagnostic Revenue, 2017-2028

6.6.2 Brazil Uterine Cancer Therapies and Diagnostic Market Size, 2017-2028

6.6.3 Argentina Uterine Cancer Therapies and Diagnostic Market Size, 2017-2028

6.7 Middle East & Africa

6.7.1 By Country - Middle East & Africa Uterine Cancer Therapies and Diagnostic Revenue, 2017-2028

6.7.2 Turkey Uterine Cancer Therapies and Diagnostic Market Size, 2017-2028

6.7.3 Israel Uterine Cancer Therapies and Diagnostic Market Size, 2017-2028

6.7.4 Saudi Arabia Uterine Cancer Therapies and Diagnostic Market Size, 2017-2028

6.7.5 UAE Uterine Cancer Therapies and Diagnostic Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 Ariad Pharmaceuticals

7.1.1 Ariad Pharmaceuticals Corporate Summary

7.1.2 Ariad Pharmaceuticals Business Overview

7.1.3 Ariad Pharmaceuticals Uterine Cancer Therapies and Diagnostic Major Product Offerings

7.1.4 Ariad Pharmaceuticals Uterine Cancer Therapies and Diagnostic Revenue in Global Market (2017-2022)

7.1.5 Ariad Pharmaceuticals Key News

7.2 Merck

7.2.1 Merck Corporate Summary

7.2.2 Merck Business Overview

7.2.3 Merck Uterine Cancer Therapies and Diagnostic Major Product Offerings

7.2.4 Merck Uterine Cancer Therapies and Diagnostic Revenue in Global Market (2017-2022)

7.2.5 Merck Key News

7.3 AbbVie

7.3.1 AbbVie Corporate Summary

7.3.2 AbbVie Business Overview

7.3.3 AbbVie Uterine Cancer Therapies and Diagnostic Major Product Offerings

7.3.4 AbbVie Uterine Cancer Therapies and Diagnostic Revenue in Global Market (2017-2022)

7.3.5 AbbVie Key News

7.4 BD

7.4.1 BD Corporate Summary

7.4.2 BD Business Overview

7.4.3 BD Uterine Cancer Therapies and Diagnostic Major Product Offerings

7.4.4 BD Uterine Cancer Therapies and Diagnostic Revenue in Global Market (2017-2022)

7.4.5 BD Key News

8 CONCLUSION

9 APPENDIX

9.1 Note

9.2 Examples of Clients

9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Uterine Cancer Therapies and Diagnostic Market Opportunities & Trends in Global Market

Table 2. Uterine Cancer Therapies and Diagnostic Market Drivers in Global Market

Table 3. Uterine Cancer Therapies and Diagnostic Market Restraints in Global Market

Table 4. Key Players of Uterine Cancer Therapies and Diagnostic in Global Market

Table 5. Top Uterine Cancer Therapies and Diagnostic Players in Global Market, Ranking by Revenue (2021)

Table 6. Global Uterine Cancer Therapies and Diagnostic Revenue by Companies, (US\$, Mn), 2017-2022

Table 7. Global Uterine Cancer Therapies and Diagnostic Revenue Share by Companies, 2017-2022

Table 8. Global Companies Uterine Cancer Therapies and Diagnostic Product Type

Table 9. List of Global Tier 1 Uterine Cancer Therapies and Diagnostic Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 10. List of Global Tier 2 and Tier 3 Uterine Cancer Therapies and Diagnostic Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 11. By Type – Global Uterine Cancer Therapies and Diagnostic Revenue, (US\$, Mn), 2021 & 2028

Table 12. By Type - Uterine Cancer Therapies and Diagnostic Revenue in Global (US\$, Mn), 2017-2022

Table 13. By Type - Uterine Cancer Therapies and Diagnostic Revenue in Global (US\$, Mn), 2023-2028

Table 14. By Application – Global Uterine Cancer Therapies and Diagnostic Revenue, (US\$, Mn), 2021 & 2028

Table 15. By Application - Uterine Cancer Therapies and Diagnostic Revenue in Global (US\$, Mn), 2017-2022

Table 16. By Application - Uterine Cancer Therapies and Diagnostic Revenue in Global (US\$, Mn), 2023-2028

Table 17. By Region – Global Uterine Cancer Therapies and Diagnostic Revenue, (US\$, Mn), 2021 & 2028

Table 18. By Region - Global Uterine Cancer Therapies and Diagnostic Revenue (US\$, Mn), 2017-2022

Table 19. By Region - Global Uterine Cancer Therapies and Diagnostic Revenue (US\$, Mn), 2023-2028

Table 20. By Country - North America Uterine Cancer Therapies and Diagnostic

Revenue, (US\$, Mn), 2017-2022

Table 21. By Country - North America Uterine Cancer Therapies and Diagnostic Revenue, (US\$, Mn), 2023-2028

Table 22. By Country - Europe Uterine Cancer Therapies and Diagnostic Revenue, (US\$, Mn), 2017-2022

Table 23. By Country - Europe Uterine Cancer Therapies and Diagnostic Revenue, (US\$, Mn), 2023-2028

Table 24. By Region - Asia Uterine Cancer Therapies and Diagnostic Revenue, (US\$, Mn), 2017-2022

Table 25. By Region - Asia Uterine Cancer Therapies and Diagnostic Revenue, (US\$, Mn), 2023-2028

Table 26. By Country - South America Uterine Cancer Therapies and Diagnostic Revenue, (US\$, Mn), 2017-2022

Table 27. By Country - South America Uterine Cancer Therapies and Diagnostic Revenue, (US\$, Mn), 2023-2028

Table 28. By Country - Middle East & Africa Uterine Cancer Therapies and Diagnostic Revenue, (US\$, Mn), 2017-2022

Table 29. By Country - Middle East & Africa Uterine Cancer Therapies and Diagnostic Revenue, (US\$, Mn), 2023-2028

Table 30. Ariad Pharmaceuticals Corporate Summary

Table 31. Ariad Pharmaceuticals Uterine Cancer Therapies and Diagnostic Product Offerings

Table 32. Ariad Pharmaceuticals Uterine Cancer Therapies and Diagnostic Revenue (US\$, Mn), (2017-2022)

Table 33. Merck Corporate Summary

Table 34. Merck Uterine Cancer Therapies and Diagnostic Product Offerings

Table 35. Merck Uterine Cancer Therapies and Diagnostic Revenue (US\$, Mn), (2017-2022)

Table 36. AbbVie Corporate Summary

Table 37. AbbVie Uterine Cancer Therapies and Diagnostic Product Offerings

Table 38. AbbVie Uterine Cancer Therapies and Diagnostic Revenue (US\$, Mn), (2017-2022)

Table 39. BD Corporate Summary

Table 40. BD Uterine Cancer Therapies and Diagnostic Product Offerings

Table 41. BD Uterine Cancer Therapies and Diagnostic Revenue (US\$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

- Figure 1. Uterine Cancer Therapies and Diagnostic Segment by Type in 2021
- Figure 2. Uterine Cancer Therapies and Diagnostic Segment by Application in 2021
- Figure 3. Global Uterine Cancer Therapies and Diagnostic Market Overview: 2021
- Figure 4. Key Caveats
- Figure 5. Global Uterine Cancer Therapies and Diagnostic Market Size: 2021 VS 2028 (US\$, Mn)
- Figure 6. Global Uterine Cancer Therapies and Diagnostic Revenue, 2017-2028 (US\$, Mn)
- Figure 7. The Top 3 and 5 Players Market Share by Uterine Cancer Therapies and Diagnostic Revenue in 2021
- Figure 8. By Type - Global Uterine Cancer Therapies and Diagnostic Revenue Market Share, 2017-2028
- Figure 9. By Application - Global Uterine Cancer Therapies and Diagnostic Revenue Market Share, 2017-2028
- Figure 10. By Region - Global Uterine Cancer Therapies and Diagnostic Revenue Market Share, 2017-2028
- Figure 11. By Country - North America Uterine Cancer Therapies and Diagnostic Revenue Market Share, 2017-2028
- Figure 12. US Uterine Cancer Therapies and Diagnostic Revenue, (US\$, Mn), 2017-2028
- Figure 13. Canada Uterine Cancer Therapies and Diagnostic Revenue, (US\$, Mn), 2017-2028
- Figure 14. Mexico Uterine Cancer Therapies and Diagnostic Revenue, (US\$, Mn), 2017-2028
- Figure 15. By Country - Europe Uterine Cancer Therapies and Diagnostic Revenue Market Share, 2017-2028
- Figure 16. Germany Uterine Cancer Therapies and Diagnostic Revenue, (US\$, Mn), 2017-2028
- Figure 17. France Uterine Cancer Therapies and Diagnostic Revenue, (US\$, Mn), 2017-2028
- Figure 18. U.K. Uterine Cancer Therapies and Diagnostic Revenue, (US\$, Mn), 2017-2028
- Figure 19. Italy Uterine Cancer Therapies and Diagnostic Revenue, (US\$, Mn), 2017-2028
- Figure 20. Russia Uterine Cancer Therapies and Diagnostic Revenue, (US\$, Mn),

2017-2028

Figure 21. Nordic Countries Uterine Cancer Therapies and Diagnostic Revenue, (US\$, Mn), 2017-2028

Figure 22. Benelux Uterine Cancer Therapies and Diagnostic Revenue, (US\$, Mn), 2017-2028

Figure 23. By Region - Asia Uterine Cancer Therapies and Diagnostic Revenue Market Share, 2017-2028

Figure 24. China Uterine Cancer Therapies and Diagnostic Revenue, (US\$, Mn), 2017-2028

Figure 25. Japan Uterine Cancer Therapies and Diagnostic Revenue, (US\$, Mn), 2017-2028

Figure 26. South Korea Uterine Cancer Therapies and Diagnostic Revenue, (US\$, Mn), 2017-2028

Figure 27. Southeast Asia Uterine Cancer Therapies and Diagnostic Revenue, (US\$, Mn), 2017-2028

Figure 28. India Uterine Cancer Therapies and Diagnostic Revenue, (US\$, Mn), 2017-2028

Figure 29. By Country - South America Uterine Cancer Therapies and Diagnostic Revenue Market Share, 2017-2028

Figure 30. Brazil Uterine Cancer Therapies and Diagnostic Revenue, (US\$, Mn), 2017-2028

Figure 31. Argentina Uterine Cancer Therapies and Diagnostic Revenue, (US\$, Mn), 2017-2028

Figure 32. By Country - Middle East & Africa Uterine Cancer Therapies and Diagnostic Revenue Market Share, 2017-2028

Figure 33. Turkey Uterine Cancer Therapies and Diagnostic Revenue, (US\$, Mn), 2017-2028

Figure 34. Israel Uterine Cancer Therapies and Diagnostic Revenue, (US\$, Mn), 2017-2028

Figure 35. Saudi Arabia Uterine Cancer Therapies and Diagnostic Revenue, (US\$, Mn), 2017-2028

Figure 36. UAE Uterine Cancer Therapies and Diagnostic Revenue, (US\$, Mn), 2017-2028

Figure 37. Ariad Pharmaceuticals Uterine Cancer Therapies and Diagnostic Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 38. Merck Uterine Cancer Therapies and Diagnostic Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 39. AbbVie Uterine Cancer Therapies and Diagnostic Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 40. BD Uterine Cancer Therapies and Diagnostic Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

I would like to order

Product name: Uterine Cancer Therapies and Diagnostic Market - Global Outlook and Forecast 2022-2028

Product link: <https://marketpublishers.com/r/U845D300A1F6EN.html>

Price: US\$ 3,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/U845D300A1F6EN.html>